Marin Jukic

Publikationer
Populärvetenskap och samverkan

Artiklar

Article: PHARMACOGENOMICS JOURNAL. 2026;26(5):34
Association between CYP2D6 genotype and treatment effectiveness and safety in 99 hospitalized patients with major depressive disorder a retrospective cohort study CYP2D6 genotype and antidepressant response
Petkovic Curcin A; Jeremic A; Jokovic D; Supic G; Simic K; Milosavljevic F; Stojanovic Z; Jukic MM
Article: JOURNAL OF AFFECTIVE DISORDERS. 2026;403:121432
Perceived stress four weeks after initiation of escitalopram monotherapy as a predictor of anxiolytic and antidepressant effects
Vukovic PG; Jeremic A; Vezmar M; Milosavljevic F; Pavlovic Z; Pesic D; Dordevic JD; Pejuskovic B; Markovic B; Ingelman-Sundberg M; Miljevic CD; Maric NP; Jukic MM
Article: BEHAVIOURAL BRAIN RESEARCH. 2026;502:116047
Tackling the interplay between the brain and kidneys: CYP2C19 mice as a preclinical tool for studying cognitive impairment in kidney disease?
Stanic D; Petrovic J; Ilic M; Nedeljkovic J; Ivanovic A; Milinkovic N; Jukic MM; Ferlicot S; Hafez G; Massy Z; Pesic V
Article: SCIENTIFIC REPORTS. 2025;15(1):32470
Effectiveness and safety of escitalopram treatment personalized based on therapeutic drug monitoring of drug plasma concentration: a prospective cohort study
Vukovic PG; Jeremic A; Vezmar M; Milosavljevic F; Pavlovic Z; Pesic D; Drakulic Dordevic J; Pejuskovic B; Markovic B; Ingelman-Sundberg M; Miljevic CD; Maric NP; Jukic MM
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2025;118(1):218-231
Improved Prediction of CYP2D6 Catalyzed Drug Metabolism by Taking Variant Substrate Specificities and Novel Polymorphic Haplotypes into Account
Johansson I; Xanthopoulou EM; Zhou Y; Sanchez-Spitman A; van Der Lee M; Wollmann BM; Storset E; Swen JJ; Guchelaar H-J; Molden E; Jukic MM; Ingelman-Sundberg M
Article: MOLECULAR AND CELLULAR NEUROSCIENCE. 2025;133:104006
Single subanesthetic dose of ketamine exerts antioxidant and antidepressive-like effect in ACTH-induced preclinical model of depression
Ivanovic A; Petrovic J; Stanic D; Nedeljkovic J; Ilic M; Jukic MM; Pejuskovic B; Pesic V
Article: JAMA NETWORK OPEN. 2024;7(8):e2425593
Pharmacogenetic Variants and Plasma Concentrations of Antiseizure Drugs
Milosavljevic F; Manojlovic M; Matkovic L; Molden E; Ingelman-Sundberg M; Leucht S; Jukic MM
Article: PHARMACEUTICALS. 2024;17(2):151
A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study
Pelgrim TAD; Philipsen A; Young AH; Juruena M; Jimenez E; Vieta E; Jukic M; Van der Eycken E; Heilbronner U; Moldovan R; Kas MJH; Jagesar RR; Noethen MM; Hoffmann P; Shomron N; Kilarski LL; van Amelsvoort T; Campforts B; van Westrhenen R
Article: NEUROSCIENCE APPLIED. 2024;3:104068
Social isolation during adolescence causes increased generalised anxiety-like behaviour in male rats and increased sociability in male and female rats
Manojlovic M; Milosavljevic F; Atanasov A; Batinic B; Sitarica P; Pesic V; Jukic MM
Article: NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY. 2023;49(1):e12867
The humanised CYP2C19 transgenic mouse exhibits cerebellar atrophy and movement impairment reminiscent of ataxia
Milosavljevic F; Brusini I; Atanasov A; Manojlovic M; Vucic M; Orescanin-Dusic Z; Brkljacic J; Miljevic C; Nikolic-Kokic A; Blagojevic D; Wang C; Damberg P; Pesic V; Tyndale RF; Ingelman-Sundberg M; Jukic MM
Article: CTS-CLINICAL AND TRANSLATIONAL SCIENCE. 2023;16(1):62-72
Impact of NFIB and CYP1A variants on clozapine serum concentration-A retrospective naturalistic cohort study on 526 patients with known smoking habits
Lenk HC; Lovsletten Smith R; O'Connell KS; Jukic MM; Kringen MK; Andreassen OA; Ingelman-Sundberg M; Molden E
Article: CTS-CLINICAL AND TRANSLATIONAL SCIENCE. 2022;15(9):2135-2145
Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population
Braten LS; Ingelman-Sundberg M; Jukic MM; Molden E; Kringen MK
Article: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. 2022;42(4):396-399
Association Between CYP2D6 Metabolizer Status and Vortioxetine Exposure and Treatment Switching A Retrospective, Naturalistic Cohort Study Using Therapeutic Drug Monitoring Data From 640 Patients
Frederiksen T; Smith RL; Jukic MM; Molden E
Article: PSYCHIATRY RESEARCH. 2022;312:114535
CYP2C19 slow metabolizer phenotype is associated with lower antidepressant efficacy and tolerability
Jokovic D; Milosavljevic F; Stojanovic Z; Supic G; Vojvodic D; Uzelac B; Jukic MM; Curcin AP
Article: CELLS. 2022;11(10):1597
Hepatocyte Thorns, A Novel Drug-Induced Stress Response in Human and Mouse Liver Spheroids
Pridgeon CS; Bolhuis DP; Milosavljevic F; Manojlovic M; Vegvari A; Gaetani M; Jukic MM; Ingelman-Sundberg M
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2022;111(5):1165-1174
The Polymorphic Nuclear Factor NFIB Regulates Hepatic CYP2D6 Expression and Influences Risperidone Metabolism in Psychiatric Patients
Lenk HC; Kloditz K; Johansson I; Smith RL; Jukic M; Molden E; Ingelman-Sundberg M
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2021;110(3):750-758
Evaluation of the CYP2D6 Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated With Three Different CYP2D6 Substrates
Jukic MM; Smith RL; Molden E; Ingelman-Sundberg M
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2021;110(3):786-793
A Novel CYP2C-Haplotype Associated With Ultrarapid Metabolism of Escitalopram
Braten LS; Haslemo T; Jukic MM; Ivanov M; Ingelman-Sundberg M; Molden E; Kringen MK
Article: PSYCHONEUROENDOCRINOLOGY. 2021;129:105234
Synergy of oxytocin and citalopram in modulating Itgb3/Chl1 interplay: Relevance to sensitivity to SSRI therapy
Stanic D; Oved K; Israel-Elgali I; Jukic M; Batinic B; Puskas N; Shomron N; Gurwitz D; Pesic V
Article: FRONTIERS IN PHARMACOLOGY. 2021;12:650750
CYP2D6 Reduced Function Variants and Genotype/Phenotype Translations of CYP2D6 Intermediate Metabolizers: Implications for Personalized Drug Dosing in Psychiatry
Molden E; Jukic MM
Visa fler

Alla övriga publikationer

Editorial: WORLD PSYCHIATRY. 2025;24(1):141-142
PSY-PGx: a new intervention for the implementation of pharmacogenetics in psychiatry
van Westrhenen R; Young AH; Heilbronner U; Juruena M; Ingelman-Sundberg M; Jukic M; Kaprio J; Kas MJH; Moldovan R; Nothen MM; Philipsen A; Shomron N; van der Eycken E; Vieta E; Schulze TG; PSY PC
Review: WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY. 2024;25(9):451-536
Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics
Hart XM; Gruender G; Ansermot N; Conca A; Corruble E; Crettol S; Cumming P; Hefner G; Frajerman A; Howes O; Jukic MM; Kim E; Kim S; Maniscalco I; Moriguchi S; Mueller DJ; Nakajima S; Osugo M; Paulzen M; Ruhe HG; Scherf-Clavel M; Schoretsanitis G; Serretti A; Spina E; Spigset O; Steimer W; Suezen SH; Uchida H; Unterecker S; Vandenberghe F; Verstuyft C; Zernig G; Hiemke C; Eap CB
Review: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2024;81:43-52
Current level of evidence for improvement of antidepressant efficacy and tolerability by pharmacogenomic-guided treatment: A Systematic review and meta-analysis of randomized controlled clinical trials
Milosavljevic F; Molden E; Ingelman-Sundberg M; Jukic MM
Letter: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2024;115(2):183
What is the Current Clinical Impact of the CYP2CTG Haplotype?
Ingelman-Sundberg M; Jukic M; Braten LS; Kringen MK; Molden E
Review: TRENDS IN PHARMACOLOGICAL SCIENCES. 2022;43(12):1055-1069
Pharmacogenomics in treatment of depression and psychosis: an update
Jukic M; Milosavljevi F; Molden E; Ingelman-Sundberg M
Review: JAMA PSYCHIATRY. 2021;78(3):270-280
Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure A Systematic Review and Meta-analysis
Milosavljevic F; Bukvic N; Pavlovic Z; Miljevic C; Pesic V; Molden E; Ingelman-Sundberg M; Leucht S; Jukic MM
Editorial: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2020;37:100-101
Can G_i1 biased 5-HT_2A inverse agonists improve the treatment of psychosis?
Jukic MM
Review: FRONTIERS IN PSYCHIATRY. 2020;11:94
Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?
van Westrenhen R; Aitchison KJ; Ingelman-Sundberg M; Jukic MM
Corrigendum: FRONTIERS IN MOLECULAR NEUROSCIENCE. 2018;11:29
Dusp 16 Deficiency Causes Congenital Obstructive Hydrocephalus and Brain Overgrowth by Expansion of the Neural Progenitor Pool (vol 10, 372, 2017)
Zega K; Jovanovic VM; Vitic Z; Niedzielska M; Knaapi L; Jukic MM; Partanen J; Friedel RH; Lang R; Brodski C
Editorial: PHARMACOGENOMICS. 2014;15(15):1841-1844
Polymorphic expression of CYP2C19 and CYP2D6 in the developing and adult human brain causing variability in cognition, risk for depression and suicide: the search for the endogenous substrates
Ingelman-Sundberg M; Persson A; Jukic MM

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI